An important implication of these observations is the possibility of overcoming resistance to BRAF/MEK-targeting therapies by combining them with BEV and/or other immune therapies in these subgroups, as has been suggested in melanoma (Hu-Lieskovan et al., 2015). The gene discussed is BRAF; the disease is melanoma.